Omicron News and Research

RSS

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Researchers assessed the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with a non-Omicron variant on SARS-CoV-2 BA.4/5 neutralization.

17 Jan 2023

Overall patterns of SARS-CoV-2 caused by variants of concern among children and adolescents

A recent study systematically reviewed COVID-19 among adolescents and children due to SARS-CoV-2 variants of concern.

17 Jan 2023

Mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months

High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months.

16 Jan 2023

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Researchers evaluated the use of receptor decoys for SARS-CoV-2 based on soluble forms of ACE2 for immunological prophylaxis and management of COVID-19 through the use of AAV vectors.

16 Jan 2023

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

Researchers from the United States evaluated the efficacy and immunogenicity of an intranasal messenger ribonucleic acid (mRNA)-lipid nanoparticle (LNP) vaccine against SARS-CoV-2 using a hamster model.

16 Jan 2023

The long-term clinical outcomes of SARS-CoV-2 infection in people with mild disease in Israel

Researchers conducted a nationwide study in Israel to determine the post-acute sequelae of SARS-CoV-2 a year after mild COVID-19.

16 Jan 2023

COVID-19 convalescent plasma transfusions significantly reduced mortality rates among hospitalized SARS-CoV-2 patients

Researchers reviewed various randomized clinical trials and cohort studies to evaluate the decrease in mortality rates among coronavirus disease 2019 (COVID-19) patients treated with COVID-19 convalescent plasma.

16 Jan 2023

What is the efficacy of the COVID-19 second booster versus the first booster with prior COVID-19 infections?

Researchers assessed the efficacy of the COVID-19 second booster vaccine compared to the first booster vaccine and the protection conferred by prior COVID-19 infection.

16 Jan 2023

Artemisia argyi plant extracts and phytochemicals shown to inhibit SARS-CoV-2 in new research

Researchers reported that Artemisia argyi extracts and phytochemicals could inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Jan 2023

Study investigates the spectrum of antibody immunity across several SARS-CoV-2 variants

Researchers evaluated antibody responses to the spike proteins of the SARS-CoV-2 Wuhan-Hu-1 strain and VOCs such as the Alpha, Beta, Gamma, Delta, and Omicron.

16 Jan 2023

SARS-CoV-2 WA1/2020, Delta and Omicron strains found to infect human sensory neurons

Researchers evaluated the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the peripheral nervous system (PNS).

13 Jan 2023

Recent findings on original antigenic sin and SARS-CoV-2

Researchers collated the findings of studies relating original antigenic sin with SARS-CoV-2 evolution.

13 Jan 2023

The 2022 U.S. RSV surge consisted of a variety of pre-existing viruses

In a recent study posted to the medRxiv* preprint server, researchers investigated whether the upsurge in respiratory syncytial virus (RSV) infections during the autumn season of 2022 occurred due to the emergence of a novel, highly transmissible RSV strain or whether multiple pre-existing RSV strains were responsible for the increase in RSV case counts during the period.

12 Jan 2023

COVID-19 booster doses could significantly reduce the incidence of SARS-CoV-2 infection among young adults

A recent study published in the journal PLOS Medicine examined the effectiveness of booster doses of coronavirus disease 2019 (COVID-19) vaccines in protecting vaccinated young adults against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections during the dominant period of the Omicron BA.1 variant.

12 Jan 2023

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

Scientists have recently conducted a cell-based high-content screening of over 300 natural compounds and identified three compounds with potent antiviral activities against SARS-CoV-2 and its variants.

12 Jan 2023

The impact of prior SARS-CoV-2 infection and vaccination on Omicron infection

researchers explored the effects of prior SARS-CoV-2 infection and vaccination on SARS-CoV-2 Omicron infection.

12 Jan 2023

Study shows booster vaccinations against SARS-CoV-2 effective but protection wanes rapidly

A recent study posted to medRxiv* assessed the effectiveness of primary and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Netherlands.

11 Jan 2023

Bivalent boosters tested against all SARS-CoV-2 Omicron lineages

In a recent study posted to the bioRxiv* preprint server, researchers in the United States assessed the impact of the bivalent messenger ribonucleic acid (mRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine on the antibody-mediated neutralization of the SARS-CoV-2 Omicron lineages.

11 Jan 2023

COVID-19 outcomes in Rituximab treated patients

A new report throws light on SARS-CoV-2 breakthrough infections in patients with certain joint diseases or musculoskeletal conditions who are on rituximab and compares the severity of COVID-19 outcomes in these patients whilst identifying potential risk factors for severe outcomes.

11 Jan 2023

2022: a year in MIS-C research

In a recent review published in Nature Reviews Rheumatology, researchers reviewed existing data on the multisystem inflammatory syndrome in children (or MIS-C).

11 Jan 2023

Omicron News and Research

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Overall patterns of SARS-CoV-2 caused by variants of concern among children and adolescents

Mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

The long-term clinical outcomes of SARS-CoV-2 infection in people with mild disease in Israel

COVID-19 convalescent plasma transfusions significantly reduced mortality rates among hospitalized SARS-CoV-2 patients

What is the efficacy of the COVID-19 second booster versus the first booster with prior COVID-19 infections?

Artemisia argyi plant extracts and phytochemicals shown to inhibit SARS-CoV-2 in new research

Study investigates the spectrum of antibody immunity across several SARS-CoV-2 variants

SARS-CoV-2 WA1/2020, Delta and Omicron strains found to infect human sensory neurons

Recent findings on original antigenic sin and SARS-CoV-2

The 2022 U.S. RSV surge consisted of a variety of pre-existing viruses

COVID-19 booster doses could significantly reduce the incidence of SARS-CoV-2 infection among young adults

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

The impact of prior SARS-CoV-2 infection and vaccination on Omicron infection

Study shows booster vaccinations against SARS-CoV-2 effective but protection wanes rapidly

Bivalent boosters tested against all SARS-CoV-2 Omicron lineages

COVID-19 outcomes in Rituximab treated patients

2022: a year in MIS-C research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News